1 jan 1998 ano - Trastuzumab
Descrição:
For the treatment of women with HER2-positive metastatic breast cancer, the Food and Drug Administration (FDA) recommends trastuzumab, a monoclonal antibody that inhibits cancer cells that overproduce the HER2 protein.
Adicionado na linha do tempo:
Cancer
Data:
